Serum sodium concentration and the progression of established chronic kidney disease

Journal of Nephrology

Volumn 32, Issue 2, 2019, Pages 259-264

  Cole, Nicholas I ^a   Suckling, Rebecca J ^a   Desilva, Vipula ^a   He, Feng J ^b   MacGregor, Graham A ^b   Swift, Pauline A ^a  

^a EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CKD progression; eGFR decline; Serum potassium; Serum sodium

Indexed keywords

LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VASOPRESSIN; BIOLOGICAL MARKER; SODIUM;

AGED; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; ENZYMATIC ASSAY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULONEPHRITIS; HEMATOCRIT; HUMAN; HYPERTENSION; INFORMATION PROCESSING; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; POTASSIUM BLOOD LEVEL; POTENTIOMETRY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; RISK FACTOR; SALT INTAKE; SODIUM BLOOD LEVEL; TREATMENT OUTCOME; VASCULITIS; BLOOD; GLOMERULUS; GLOMERULUS FILTRATION RATE; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; SODIUM; TIME FACTORS;

EID: 85055587523     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-018-0541-z     Document Type: Article

References (23)

1. McMahon EJ, Campbell KL, Bauer JD, Mudge DW (2015) Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev 2:CD010070
2. de Wardener HE, He FJ, MacGregor GA (2004) Plasma sodium and hypertension. Kidney Int 66:2454–2466
3. He FJ, Markandu ND, Sagnella GA, de Wardener HE, MacGregor GA (2005) Plasma sodium: ignored and underestimated. Hypertension 45:98–102
4. Friedman SM, McIndoe RA, Tanaka M (1990) The relation of blood sodium concentration to blood pressure in the rat. J Hypertens 8:61–66
5. Suckling RJ, Swift PA, He FJ, Markandu ND, MacGregor GA (2013) Altering plasma sodium concentration rapidly changes blood pressure during haemodialysis. Nephrol Dial Transpl 28:2181–2186
6. Oberleithner H, Riethmüller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M (2007) Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci 104:16281–16286
7. Oberleithner H, Peters W, Kusche-Vihrog K, Korte S, Schillers H, Kliche K, Oberleithner K (2011) Salt overload damages the glycocalyx sodium barrier of vascular endothelium. Pflugers Arch 462:519–528
8. Gu J-W, Sartin A, Elam J, Adair TH (2000) Dietary salt induces gene expression of hypertrophy-related factors in cultured human endothelial cells. Am J Hypertens 13(Suppl 2):F015
9. Loeffler I, Wolf G (2014) Transforming growth factor-beta and the progression of renal disease. Nephrol Dial Transpl 29(Suppl 1):i37–i45
10. Kovesdy CP, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Molnar MZ, Kalantar-Zadeh K (2012) Hyponatraemia, hypernatraemia, and mortality in patients with chronic kidney disease with and without congestive cardiac failure. Circulation 125:677–684
11. Han SW, Tilea A, Gillespie BW, Finkelstein FO, Kiser MA, Eisele G, Kotanko P, Levin N, Saran R (2015) Serum sodium levels and patient outcomes in an ambulatory clinic-based chronic kidney disease cohort. Am J Nephrol 41:200–209
12. Chiu DY, Kalra PA, Sinha S, Green D (2016) Association of serum sodium levels with all-cause and cardiovascular mortality in chronic kidney disease: Results from a prospective observational study. Nephrology 21:476–482
13. Huang H, Jolly SE, Airy M, Arrigain S, Schold JD, Nally JV, Navaneethan SD (2017) Associations of dysnatremias with mortality in chronic kidney disease. Nephrol Dial Transpl 32:1204–1210
14. Nakajima K, Oda E, Kanda E (2016) The association of serum sodium and chloride levels with blood pressure and estimated glomerular filtration rate. Blood Press 25:51–57
15. Kuwabara M, Hisatome I, Roncal-Jimenez CA, Niwa K, Andres-Hernando A, Jensen T, Bjornstad P, Milagres T, Cicerchi C, Song Z, Garcia G, Sánchez-Lozada LG, Ohno M, Lanaspa MA, Johnson RJ (2017) Increased serum sodium and serum osmolarity are independent risk factors for developing chronic kidney disease; 5 year cohort study. PLoS One 12:e0169137
16. 2 . Am J Kidney Dis 56:486–495
17. Clark WF, Sontrop JM, Huang SH, Moist L, Bouby N, Bankir L (2016) Hydration and chronic kidney disease progression: a critical review of the evidence. Am J Nephrol 43:281–292
18. Clark WF, Sontrop JM, Huang SH, Gallo K, Moist L, House AA, Cuerden MS, Weir MA, Bagga A, Brimble S, Burke A, Muirhead N, Pandeya S, Garg AX (2018) Effect of coaching to increase water intake on kidney function decline in adults with chronic kidney disease: the CKD WIT randomized clinical trial. JAMA 319:1870–1879
19. Zerbe RL, Robertson GL (1983) Osmoregulation of thirst and vasopressin secretion in human subjects: effect of various solutes. Am J Physiol 244:E607–E614
20. Zittema D, van den Brand JAJG, Bakker SJL, Wetzels JF, Gansevoort RT (2017) Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients. Nephrol Dial Transpl 32(suppl 1):i146–i153
21. Boertien WE, Meijer E, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP (2013) Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis 61:420–429
22. Zhang Z, Duckart J, Slatore CG, Fu Y, Petrik AF, Thorp ML, Cohen DM (2014) Individuality of the plasma sodium concentration. Am J Physiol Renal Physiol 306:F1534–F1543
23. Bricker NS, Dewey RR, Lubowitz H, Stokes J, Kirkensgaard T (1959) Observations on the concentration and diluting mechanisms of the diseased kidney. J Clin Invest 38:516–523